From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics
Cody A Loy, Yijun Gu, Samuel C Kim, Mariam V Mohagheghi, Noah B Trask, Marina Suarez-Pizarro, Lisa E Wagar, Claudia A Benavente, Darci J Trader · 2026
Read From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics by Cody A Loy, Yijun Gu, Samuel C Kim, Mariam V Mohagheghi, Noah B Trask, Marina Suarez-Pizarro, Lisa E Wagar, Claudia A Benavente, Darci J Trader (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13470457.txt.
Description
Developing novel strategies that can exploit a cell's endogenous machinery to selectively release toxic compounds in diseased cells, while leaving healthy cells unaffected, is a challenging task to accomplish. An established approach involves antigen recognition on tumor cells, enabling targeted delivery of prodrugs in which a cytotoxic compound is appended to an antibody by a cleavable linker.
Catalog record
| CREATOR | Cody A Loy, Yijun Gu, Samuel C Kim, Mariam V Mohagheghi, Noah B Trask, Marina Suarez-Pizarro, Lisa E Wagar, Claudia A Benavente, Darci J Trader |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |